(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Retinoblastoma Program is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.
James J. Augsburger, MD Co-Director, Retinoblastoma Program 513-475-7300
Co-Director, Retinoblastoma Program
Ocular Oncologist, Division of Pediatric Ophthalmology
Professor, UC Department of Ophthalmology
Retinoblastoma; medulloepithelioma; retinal and choroidal hemangiomas; conjunctival tumors; iris tumors
James J. Augsburger, MD, is professor and chairman of the Department of Ophthalmology at the University of Cincinnati College of Medicine and chief of the Ocular Oncology Service at the University of Cincinnati Medical Center. He specializes in the diagnosis and treatment of eye tumors, including uveal and conjunctival melanomas, retinoblastomas, metastatic carcinomas to the eye, ocular lymphomas, hemangiomas of the retina and choroid, and other benign and malignant tumors in or on the eye.
Dr. Augsburger completed his undergraduate studies at Heidelberg College, Tiffin, Ohio. After receiving his Doctor of Medicine from the University of Cincinnati College of Medicine, he completed his internship at the Cleveland Clinic Foundation in Cleveland, Ohio. Dr. Augsburger then completed his residency at the University of Cincinnati Medical Center, followed by a fellowship in retina and ocular oncology at Wills Eye Hospital, Philadelphia, PA. He joined the attending staff of Wills Eye Hospital immediately following this fellowship and remained there in ocular oncology practice until his relocation to Cincinnati in 1999.
Dr. Augsburger is a board certified diplomate of the American Board of Ophthalmology and a fellow of the American Academy of Ophthalmology. He also belongs to the American Ophthalmological Society, ARVO (Association of Research in Vision and Ophthalmology), AUPO (Association of University Professors of Ophthalmology), Club Jules Gonin (European Retina Society), Macula Society and Retina Society.
BS: Heidelberg College, Tiffin, OH, 1970.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 1974.
Internship: Cleveland Clinic, Cleveland, OH, 1974-1975.
Residency: Ophthalmology, University of Cincinnati Medical Center, University of Cincinnati, Cincinnati, OH, 1975-1978.
Fellowship: Retina-Vitreous & Ocular Oncology, Wills Eye Hospital, Philadelphia, PN, 1978-1980.
Board Certification: American Board of Ophthalmology, 1979.
James I. Geller, MD Medical Director, Kidney and Liver Tumors Program 513-636-4266 firstname.lastname@example.org
Medical Director, Kidney and Liver Tumors Program
Co-Medical Director, Retinoblastoma Program
Associate Director, Global Cancer Programs
Associate Professor, UC Department of Pediatrics
Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology
James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of associate professor of pediatrics.
Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare / Retinoblastoma Committee as both a steering/voting member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as steering/voting member, RTC Sub-Committee chair of developmental therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.
MD: Sackler School of Medicine, 1997.
Residency: New York Medical College, 2000.
Fellowship: St Jude Children's Research Hospital, 2004.
Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.
Geller JI, Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep;41(9):1183-97.
Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7.
Cripe TP. Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer. 2009 Aug;53(2):133-5.
Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer. 2009 Mar;52(3):430.
Geller JI, Leslie ND, Yin H. Malignant Rhabdoid Tumor. eMedicine from WebMD. 2009 Dec. Available online.
Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.
Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer. 2008 Sep 1;113(5):893-6.
Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008 Apr 1;112(7):1607-16.
Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer. 2006 Apr;46(4):527.
Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004 Oct 1;101(7):1575-83.
Zelia M. Correa, MD, PhD Ophthalmologist, Division of Pediatric Ophthalmology 513-475-7300 email@example.com
Ophthalmologist, Division of Pediatric Ophthalmology
Associate Professor, UC Department of Ophthalmology
Ocular oncology; retinoblastoma and childhood ocular benign and malignant tumors
Dr. Correa has been recognized by her academic achievements and her volunteer service/leadership in the profession of ophthalmology. She has received an achievement award (2010) and the international ophthalmologist education award (2009) from the American Academy of Ophthalmology. Additionally, she has been recognized by two Secretariat Awards also from the American Academy of Ophthalmology and has been the youngest Guest of Honor at their National Meeting in 2009. Here in Cincinnati, she has received the Dean’s Award for Excellence in Education (University of Cincinnati College of Medicine) in 2011.
Undergraduate: Faculdade Riopretense de Filosofia Ciências e Letras, São José do Rio Preto, Brazil.
MD: Faculdade Medicina de Rio Preto, São José do Rio Preto, Brazil, 1989.
Residency: Ophthalmology, Faculdade de Medicina de Marília, Brazil, 1992.
Certification: Ophthalmology, 1992.
Fellowship: Vitreoretinal surgery, Brazil, 1995.
Fellowship: Ocular oncology, Wills Eye Hospital, Philadelphia, PA, 1996.
PhD: UNIFESP (Federal university of São Paulo, SP, Brazil), 2003.
Post-doctoral fellowships: Ophthalmic pathology, Wills Eye Institute, Philadelphia, PA, 2005.
Ophthalmic pathology and translational research, McGill University-Montreal, QC, Canada, 2006.
Correa ZM, Augsburger JJ. Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. Graefes Arch Clin Exp Ophthalmol. 2013 Nov 24. [Epub ahead of print].
Augsburger JJ, Corrêa ZM, Trichopoulos N. Prognostic implications of cytopathologic classification of melanocytic uveal tumors evaluated by fine-needle aspiration biopsy. Arq Bras Oftalmol. 2013 Mar-Apr;76(2):72-9.
Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, Harocopos GJ, Hovland PG, McGowan HD, Milman T, Mruthyunjaya P, Simpson ER, Smith ME, Wilson DJ, Wirostko WJ, Harbour JW. Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma. Ophthalmology. 2012 Aug;119(8):1596-603.
Simoes CC, Call MK, Correa ZM, Spaulding AG, Augsburger JJ. Clinical and histopathological features and immunoreactivity of human choroidal and ciliary body melanomas as prognostic factors for metastasis and death. Graefes Arch Clin Exp Ophthalmol. 2011;249(12):1795-803.
Augsburger JJ, Correa ZM, Trichopoulos N. Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival. Am J Ophthalmol. 2011 July;152(1):5-9.
Palakurthi NK, Correa ZM, Augsburger JJ, Banerjee RK. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study. J Ocul Pharmacol Ther. 2011 Apr;27(2):151-6.
Correa ZM, Marshall JC, Souza Filho JP, Odashiro AN, Burnier Jr MN. Fine needle aspiration biopsy to reestablish cell culture in an animal model of uveal melanoma. Arq Bras Oftalmol. 2009 Jul-Aug;72(4):515-8.
Augsburger JJ, Corrêa ZM, Shaikh AH. Quality of evidence about effectiveness of treatments for metastatic uveal melanoma. Trans Am Ophthalmol Soc. 2008;106:128-35; discussion 135-7.
Augsburger JJ, Corrêa ZM, Trichopoulos N, Shaikh A. Size overlap between benign melanocytic choroidal nevi and choroidal malignant melanomas. Invest Ophthalmol Vis Sci. 2008 Jul;49(7):2823-8.
Augsburger JJ, Corrêa ZM, Schneider S, Yassin RS, Robinson-Smith T, Ehya H, Trichopoulos N. Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category. Trans Am Ophthalmol Soc. 2002;100:225-32; discussion 232-4.
Rajaram Nagarajan, MD, MS Associate Director, Oncology Clinical Operations 513-636-0670 firstname.lastname@example.org
Associate Director, Oncology Clinical Operations
Bone tumors; late effects of pediatric cancer therapy
BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.
MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.
Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.
Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.
MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002.
Certifications: Pediatrics, Pediatric Hematology / Oncology.
Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011 Feb 1;117(3):625-34.
Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3.
Nagarajan R. Quality of life (QOL) in patients with osteosarcoma. Recent Results Cancer Res. 2009;179:339-44.
Nagarajan R, Mogil R, Neglia JP, Robison LL, Ness KK. Self-reported global function among adult survivors of childhood lower-extremity bone tumors: a report from the Childhood Cancer Survivor Study (CCSS). J Cancer Surviv. 2009 Mar;3(1):59-65.
Zebrack BJ, Zevon MA, Turk N, Nagarajan R, Whitton J, Robison LL, Zeltzer LK. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007 Jul;49(1):47-51.
Khan K, Schwarzenberg SJ, Sharp H, Jessurun J, Gulbahce HE, Defor T, Nagarajan R. Diagnostic endoscopy in children after hematopoietic stem cell transplantation. Gastrointest Endosc. Sep 2006;64(3):379-85.
Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clinical Obstetrics and Gynecology. Sep 2006; 49(3):464-79.
Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep. 2005 Nov;7(6):410-4.
Nagarajan R, Robison LL. Pregnancy outcomes in survivors of childhood cancer. J Natl Cancer Inst Monogr. 2005;(34):72-6.
Spector LG, Ross JA, Nagarajan R. Epidemiology of bone and soft tissue sarcomas. In Pappo A (Ed.) Pediatric Bone and Soft Tissue Tumors. 1st ed. Berlin: Springer-Verlag, 2006.
Todd Abruzzo, MD Chief, Pediatric Interventional Neuroradiology, Department of Radiology and Medical Imaging 513-803-2758 email@example.com
Chief, Pediatric Interventional Neuroradiology, Department of Radiology and Medical Imaging
Professor, UC Department of Radiology
Pediatric interventional neuroradiology
Todd Abruzzo, MD, has helped establish a national referral center for pediatric vascular malformations, hereditary hemorrhagic telangiectasia, and retinoblastoma at Cincinnati Children’s Hospital Medical Center. He plays a major role in the endovascular treatment of children at Cincinnati Children’s. Through close collaboration with other members of the Fetal Care Program at Cincinnati Children’s, he has helped to develop a comprehensive care plan for children with vein of Galen malformations and other congenital vascular anomalies. While working with other physicians, he has helped build a nationally recognized program for the treatment of retinoblastoma with intra-arterial chemotherapy.
Rahme R, Farley CW, Zuccarello M, Ringer AJ, Khan U, Abruzzo TA. Transarterial embolization of cerebral arteriovenous malformations: A durable treatment for venous side hemorrhage? Med Hypotheses. 2011 Jun;76(6):827-30.
Abruzzo TA, Heran MK. Neuroendovascular therapies in pediatric interventional radiology. Tech Vasc Interv Radiol. 2011 Mar;14(1):50-6.
Grande A, Nichols C, Khan U, Pyne-Geithman G, Abruzzo T, Ringer A, Zuccarello M. Treatment of post-hemorrhagic cerebral vasospasm: role of endovascular therapy. Acta Neurochir Suppl. 2011;110(Pt 2):127-32.
Greiner HM, Abruzzo TA, Kabbouche M, Leach JL, Zuccarello M. Rotational vertebral artery occlusion in a child with multiple strokes: a case-based update. Childs Nerv Syst. 2010 Dec;26(12):1669-74. Hitchcock KE, Caudell DN, Sutton JT, Klegerman ME, Vela D, Pyne-Geithman GJ, Abruzzo T, Cyr PE, Geng YJ, McPherson DD, Holland CK. Ultrasound-enhanced delivery of targeted echogenic liposomes in a novel ex vivo mouse aorta model. J Control Release. 2010 Jun 15;144(3):288-95.
Xu, DS., Abruzzo T, Albuquerque FC, Dabus G, Eskandari MK, Guterman LR, Hage ZA, Hurley MC, Hanel RA, Levy EI, Nichols CW, Ringer AJ, Batjer HH, Bendok BR. External carotid artery stenting to treat patients with symptomatic ipsilateral internal carotid artery occlusion: a multicenter case series. Neurosurgery. 2010 Aug;67(2):314-21.
Jones B, Morales H, Abruzzo T, Mangano F, Leach J. Documented Development of Dural Arteriovenous Fistula in an Infant Subsequent to Sinus Thrombosis. Neuroradiology. 2010 Mar;52(3):225-9.
Khan SN, Adeoye O, Shutter L, Abruzzo T, Ringer AJ. Intracranial dural sinus thrombosis: novel use of a mechanical thrombectomy catheter and review of management strategies. Clinical Medicine and Research. 2009 Dec;7(4):157-65.
Kocaeli H, Chaalala C, Abruzzo T, Zuccarello M. Results of modern surgical management for posterior cerebral artery aneurysms: seven year experience in the endovascular era. Acta Neurochirurgica. 2009 Dec;151(12):1583-91.Khan SNH, Abruzzo T, Ringer AJ. Successful endovascular reconstruction of acutely ruptured pseudoaneurysm of the vertebral artery, complicated by isolated vertebrobasilar circulation and symptomatic vasospasm. Clinical Neurology and Neurosurgery. 2009 Dec;111(10):868-73.
Nancy Doan Leslie, MD Interim Co-Director, Division of Human Genetics 513-636-2438 firstname.lastname@example.org
Interim Co-Director, Division of Human Genetics
Director, Clinical Genetics Fellowship Program
Professor, UC Department of Pediatrics
Galactosemia; PKU; inborn errors; newborn screening; lysosomal storage disease
MD :Washington University, St. Louis, MO, 1975-1979.
Internship and Residency: University of Cincinnati College of Medicine, Cincinnati, OH.
Fellowship: Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center,OH, 1982-1985; Clinical Genetics and Clinical Biochemical Genetics, Cincinnati Children's Hospital Medical Center, OH, 1993-1995.
Certification: American Board of Pediatrics, 1986; American Board of Pediatrics, Sub-Board of Pediatric Endocrinology, 1989; American Board of Medical Genetics, Board-Certified in Clinical Genetics and Clinical Biochemical Genetics, 1996, Active in MOC.
Slaughter JL, Meinzen-Derr J, Rose SR, Leslie ND, Chandrasekar R, Linard SM, Akinbi HT. The effects of gestational age and birth weight on false-positive newborn-screening rates. Pediatrics. 2010 Nov;126(5):910-6.
Dalal P, Leslie ND, Lindor NM, Gilbert DL, Espay AJ. Motor tics, stereotypies, and self-flagellation in primrose syndrome. Neurology. 2010 Jul 20;75(3):284-6.
Gilbert DL, Leslie EJ, Keddache M, Leslie ND. A novel hereditary spastic paraplegia with dystonia linked to chromosome 2q24-2q31. Mov Disord. 2009 Feb 15;24(3):364-70.
Burrow TA, Leslie ND. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics. 2008 Jun;2(2):311-20.
Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr. 2007 Dec;19(6):628-35. Review.
Halperin J, Devi SY, Elizure S, Stocco C, Shehu A, Rebourcet D, Unterman TG, Leslie ND, Le J, Binart N, Gibori, G. Prolactin signaling through the Short form of Its Receptor Represses Forkhead Transcription Factor FOXO3 and its Target Gene GALT Causing a Severe Ovarian Defect. Molecular Endocrinology. 2008 22:513-22.
Leslie, ND. Inborn errors and Pediatric Critical Care. In Wheeler, D ed. Pediatric Critical Care Medicine: Basic Science and Clinical Evidence. Springer 2007.
Tinkle B, Lesli ND. Pompe Disease. Gene Clinics. 2007.
Grabowski GA, Hopkin RJ, Burrow RA, Leslie ND, Tinkle BT. Enzyme Reconstitution/Replacement Therapy for Lysosomal Storage Diseases. Current Opinion in Pediatrics. 2007 19:628-35.
Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu W, Leslie N, Levine J, Spencer C, McDonald M, DuMontier J, Michael H, Chien Y, Hopkin R, Vijayaraghavan S, Bruskin D, Barholomew D, van der Ploeg A, Clancy J, Prarin R, Morin G, Beck N, Delagastine G, Jokin M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE. Recombinant Human Acid -Alpha Glucosidase: Major Clinical Benefits in Infantile-Onset Pompe Disease. Neurology. 2007 68(2):99-109.
Lionel M.L. Chow, MD, PhD Member, Cancer Biology and Neural Tumors Program 513-803-1369 email@example.com
Member, Cancer Biology and Neural Tumors Program
St. Baldrick’s Foundation Scholar
Sontag Foundation Distinguished Scientist
Assistant Professor, UC Department of Pediatrics
Lionel Chow, MD, PhD, received his medical and graduate degrees from McGill University in Montreal, Canada, where his research focused on the regulation of T-lymphocyte signaling by the intracellular tyrosine protein kinases Lck and Csk.
Following his clinical training in pediatrics and pediatric hematology / oncology at the Hospital for Sick Children in Toronto, Canada, he moved to St. Jude Children’s Research Hospital in Memphis, Tenn., to pursue his research interests.
Chow's research interests have been centered on glioblastoma multiforme, a particularly devastating form of cancer in adults and children. His work has resulted in the development of a number of novel and robust laboratory models for this disease. Using these models and interfacing with clinical trials in the Neuro-Oncology Program as well as those from national consortia such as the Children's Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC), Chow’s laboratory will continue research in this area with the goals of better understanding the origins of this form of cancer and improving patient outcomes.
PhD: McGill University, Montreal, Quebec, Canada, 1996.
MDCM: McGill University, Montreal, Quebec, Canada, 1997.
Residency: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 1997-2000.
Clinical Fellowship: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 2000-2003.
Postdoctoral Fellowship: St. Jude Children’s Research Hospital, Memphis, TN, 2003-2009.Clinical Fellowship: St. Jude Children’s Research Hospital, Memphis TN, 2008-2009.
Certification: Pediatrics, 2000.
Hummel, TR, Chow, LML, Fouladi, M, and Franz, D. Pharmacotherapeutic management of pediatric astrocytomas: current and upcoming strategies. Pediatric Drugs 2013; 15:29-42.
Joshi, K, Banasavadi-Siddegowda, Y, Mo, X, Kim, SH, Mao, P, Kig, C, Nardini, D, Sobol, RW, Chow, LML, Kornblum, HI, Waclaw, R, Beullens, M, and Nakano, I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013; 31:1051-1063.
Zhong, Y, Wan, Y-W, Pang, K, Chow, LML, and Liu, Z. Digital sorting of complex tissues for cell type-specific gene expression profiles. BMC Bioinformatics 2013; 14:89.
Rafalski, VA, Ho, PP, Brett, JO, Ucar, D, Dugas, JC, Pollina, EA, Chow, LML, Ibrahim, A, Baker, SJ, Barres, BA, Steinman, L, and Brunet, A. Expansion of oligodendrocyte progenitor cells upon SIRT1 inactivation in the adult brain. Nature Cell Biol. 2013; 15:614-624.
Wojton, J, Chu, Z, Mathsyaraja, H, Meisen, WH, Denton, N, Kwon, C-H, Chow, LML, Palascak, M, Franco, R, Bourdeau, T, Thornton, S, Ostrowski, MC, Kaur, B, and Qi, X. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol. Ther. 2013; 21:1517-1525.
Chow LML, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. Cooperativity within and among Pten, p53 and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011;19:305-316.
Lavado A, Lagutin O, Chow LML, Baker SJ, Oliver G. Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis. PLoS Biol. 2010;8:e1000460.
Cicero SA, Johnson D, Reyntjens S, Frase S, Connell S, Chow LML, Baker SJ, Sorrentino BP, Dyer MA. Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci U S A. 2009 Apr;106(16):6685-90.
Weber T, Corbett MK, Chow LML, Valentine MB, Baker SJ, Zuo J. Rapid cell-cycle reentry and cell death after acute inactivation of the retinoblastoma gene product in postnatal cochlear hair cells. Proc Natl Acad Sci U S A. 2008;105(2):781-5.
Chow LML, Zhang J, Baker SJ. Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells. Transgenic Res. 2008;17(5):919-28.
Biplab Dasgupta, PhD, MS Member, Cancer Biology and Neural Tumors Program 513-803-1370 firstname.lastname@example.org
Biplab Dasgupta, PhD, MS, completed his doctorate in molecular biology and immunology at the Indian Institute of Chemical Biology, Calcutta, and a postdoctoral fellowship at Washington University School of Medicine, Saint Louis. Dr. Dasgupta came to Cincinnati Children's Hospital Medical Center in August 2009 as an assistant professor of pediatrics within the University of Cincinnati College of Medicine. He is interested in understanding how neural cell / stem cell metabolic and energy status is linked to cell cycle, lineage commitment, differentiation and tumorigenesis. His other interests include genetic, developmental, post-translational, tissue- and stimuli–specific regulation of the subunits that constitute the AMP kinase complex.
PhD: Indian Institute of Chemical Biology, Calcutta, 2003.
Postdoctoral Fellowship: Washington University School of Medicine, Saint Louis.
Xiaona Liu, Rishi Raj Chhipa and Biplab Dasgupta*. The Selective AMPK inhibitor Compound C is a potent AMPK-independent anti-glioma agent. Mol Cancer Ther. *Corresponding author. 2014 Mar:13(3):596-605
Xiaona Liu, Rishi Raj Chhipa, Shabnam Pooya, Matthew Wortman, Sara Yachishin, Ashish Kumar, Lionel Chow, Xuan Zhou, Ying Sun, Brian Quinn, Christopher McPherson, Ronald Warnick, Adi Kendler, Sailendra Giri, Jeroen Poels, Koennard Nogra, Benoit Viollet, Gregory A. Grabowski and Biplab Dasgupta*. Novel mechanisms of mTOR and cdc25c regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sc U S A. *Corresponding author. 2014 Jan 28;111(4):E435-44.
Karkare S, Chhipa RR, Anderson J, Liu X, Henry H, Gasilina A, Nassar N, Roychoudhury J, Clark JP, Kumar A, Pauletti GM, Ghosh PK, Dasgupta B*. Direct inhibition of Retinoblastoma phosphorylation by Nimbolide causes cell cycle arrest and suppresses glioblastoma growth. Clin Cancer Research. 2014 Jan 1:20(1):199-212.
Dasgupta B, Ju JS, Sasaki Y, Liu X, Jung SR, Higashida K, Lindquist D, Milbrandt J. The AMPK beta2 subunit is required for energy homeostasis during metabolic stress. Mol Cell Biol. 2012; 32: 2837-48. Cover article. *Corresponding author.
Dasgupta B, Milbrandt J. AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell. 2009 Feb;16(2):256-70.
Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007 Apr;24;104(17):7217-22.
Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell. 2007 Oct 11;1(4):443-57.
Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005 Jun 8;25(23):5584-94.
Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005 Apr 1;65(7):2755-60.
Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005 Jan 1;65(1):236-45.
Richard A. Lang, PhD Director, Visual Systems Group 513-636-2700 email@example.com
Director, Visual Systems Group
UC Department of Ophthalmology
Wnt ligands in tumorigenesis; vascular regression and tissue regeneration; lens induction and morphogenesis.
Visit the Lang Lab.
BSc: Co-major in genetics and biochemistry, University of Melbourne, Australia, 1984 (with honors).
PhD: University of Melbourne, Australia, at the Ludwig Institute for Cancer Research under Drs. AR Dunn and TJ Gonda, 1988.
Postdoctoral Fellow: The G.W. Hooper Research Foundation, University of California, San Francisco under Dr. JM Bishop, 1989-92. Studied the role of the macrophage in developmentally programmed tissue remodeling.
Carpenter AC, Rao S, Wells JM, Campbell K, Lang RA. Generation of mice with a conditional null allele for Wntless. Genesis. 2010 Sep;48(9):554-8.
Pandey RN, Rani R, Yeo EJ, Spencer M, Hu S, Lang RA, Hegde RS. The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene. 2010 Jun 24;29(25):3715-22.
Plageman TF Jr, Chung MI, Lou M, Smith AN, Hildebrand JD, Wallingford JB, Lang RA. Pax6-dependent Shroom3 expression regulates apical constriction during lens placode invagination. Development. 2010 Feb;137(3):405-15.
Smith AN, Radice G, Lang RA. Which FGF ligands are involved in lens induction? Dev Biol. 2010 Jan 15;337(2):195-8.
Chauhan BK, Disanza A, Choi SY, Faber SC, Lou M, Beggs HE, Scita G, Zheng Y, Lang RA. Cdc42- and IRSp53-dependent contractile filopodia tether presumptive lens and retina to coordinate epithelial invagination. Development. 2009 Nov;136(21):3657-67.
Smith AN, Miller LA, Radice G, Ashery-Padan R, Lang RA. Stage-dependent modes of Pax6-Sox2 epistasis regulate lens development and eye morphogenesis. Development. 2009 Sep;136(17):2977-85. Erratum in: Development. 2009 Oct;136(19):3377.
Rao S, Lobov IB, Vallance JE, Tsujikawa K, Shiojima I, Akunuru S, Walsh K, Benjamin LE, Lang RA. Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch. Development. 2007 Dec;134(24):4449-58.
Song N, Schwab KR, Patterson LT, Yamaguchi T, Lin X, Potter SS, Lang RA. pygopus 2 has a crucial, Wnt pathway-independent function in lens induction. Development. 2007 May;134(10):1873-85.
Schwab KR, Patterson LT, Hartman HA, Song N, Lang RA, Lin X, Potter SS. Pygo1 and Pygo2 roles in Wnt signaling in mammalian kidney development. BMC Biol. 2007 Apr 10;5:15.
Miller LA, Smith AN, Taketo MM, Lang RA. Optic cup and facial patterning defects in ocular ectoderm beta-catenin gain-of-function mice. BMC Dev Biol. 2006 Mar 15;6:14.
Nancy Ratner, PhD Beatrice C. Lampkin Chair, Cancer Biology 513-636-9469 firstname.lastname@example.org
Beatrice C. Lampkin Chair, Cancer Biology
Program Leader, Cancer and Biology and Neural Tumors Program
Preclinical testing in neurofibromatosis tumors
Nancy Ratner, PhD, is interested in understanding mechanisms of peripheral nerve tumor (neurofibroma) formation in neurofibromatosis type 1 (NF1), a common inherited disorder in which children are predisposed to cancer of the nervous system, to learning problems, bone disorders, and other cancers. She identified EGFR and MEK as potential therapeutic targets in NF1 peripheral nerve tumorigenesis, and has developed cell culture and mouse models of NF1 nerve tumorigenesis. Her laboratory has also used analysis of gene expression to identify critical genes in neurofibroma and their malignant derivatives, MPNST.
Dr. Ratner received her bachelor's from Brown University, her doctorate from Indiana University, and was a postdoctoral fellow at Washington University in St. Louis. She was a member of the faculty at the University of Cincinnati from 1987 to 2004. Dr. Ratner is currently a professor in the Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, and the program leader for Cancer Biology and Neural Tumors Program in the Cancer and Blood Diseases Institute where she holds the Beatrice C. Lampkin Endowed chair in cancer biology and serves as PI of the NINDS P50 “Cincinnati Center in NF Research.”
Dr. Ratner is an active member of the International Consortium on the Molecular Biology of NF1, NF2, and Schwannomatosis and was a member of the advisory board for the National Neurofibromatosis Foundation (now Children’s Tumor Foundation) from 1989 to 2007. She chaired the Department of Defense Neurofibromatosis Research Program Integration Panel in 2008, and currently serves as a member of the James McDonnell Brain Tumor Research Advisory Board. She received the von Recklinghausen Award from the Children’s Tumor Foundation in 2010 and the Jacob K. Javits Neuroscience Investigator Award (NIH-NINDS MERIT Award) in 2014.
PhD: Indiana University, 1982.
BA: Brown University, 1975.
Fellowship: Washington University St. Louis, 1982-1987.
Mayes DA, Rizvi TA, Titus-Mitchell HA, Oberst R, Ciraolo GM, Vorhees CV, Robinson AP, Miller SD, Stemmer-Rachamimov AO, Ratner N. Nf1 loss and Ras activation in Oligodendrocytes induce NOS-driven Defects in Myelin and Vasculature. Cell Reports. 2013 Sep 26;4(6):1197-212.
Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity B, Beckmann DA, Wolf N, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra S, Ratner N, Largaespada DA. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies novel genes and genetic pathways driving tumorigenesis. Nature Genetics. 2013;45(7):756-66.
Watson AL, Rahrmann EP, Moriarity B, Choi K, Conboy C, Greeley A, Halfond A, Anderson L, Wahl B, Keng VW, Rizzardi A, Forser C, Collins MH, Sarver A, Wallace M, Schmechel S, Ratner N, Largaespada DA. Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance. Cancer Discov. 2013 Jun;3(6):674-689.
Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, West BL, Bollag G, Ratner N. Neurofibroma associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neurpathol. 2013;125(1):159-68.
Jessen WJ, Miller SJ, Jousma E, Rizvi TA, Eaves D, Wu J, Widemann B, Kim M-O, Dombi E, Dudley AH, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N. MEK Inhibition Exhibits Efficacy in Human and Mouse Neurofibromatosis Tumors Despite Transcriptional Feedback onto ERK. J Clin. Invest. 2013 Jan 2;123(1):340-7.
Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N. Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target. Clin Canc Res. 2012 Sep 15;18(18):5020-30.
Hennigan RF, Moon CO, Parysek LM, Monk KR, Morfini G, Berth S, Brady ST, Ratner N. Merlin Modulates Microtubule-Based Vesicle Trafficking via Rac, MLK and p38SAPK. Oncogene. 2012;29(3):368-79.
Mayes DA, Rizvi TA, Cancelas JA, Kolasinski NT, Ciraolo GM, Stemmer-Rachamimov AO, Ratner N. Perinatal or Adult Nf1 Inactivation Using Tamoxifen-Inducible PlpCre Each Cause Neurofibroma Formation. Cancer Res. 2011 Jul 1;71(13):4675-85.
Hummel TR, Jessen WJ, Miller SC, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page G, Worley P, Aronow BJ, Schorry E, Ratner N. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res. 2010;16 5048-57.
Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga A, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N. Integrative genomic analyses of neurofibromatosis tumors identify SOX9 as biomarker and survival gene. EMBO Mol Medicine. 2009 1(4): 236-48.
Mitogenic Activities in Neurofibromatosis. Principle Investigator. Sept 2011-2016. NIH-R01 NS 28840-20.
Preclinical Testing: GEM-Neurofibroma. Principal Investigator. Children's Tumor Foundation. Aug 2013-Jul 2016.
Identification of Neurofibroma Growth and Drug Resistance Pathways. Principal Investigator. Neurofibromatosis Therapeutic Acceleration Program (NTAP). Apr 2014-Mar 2016.
Ras Proteins in Nerve Tumorigenesis. Principal Investigator. Apr 2014-Mar 2019. 1R01 NS083580-01A1.
Novel Combinatorial Therapies for Malignant Peripheral Nerve Sheath Tumors. Co-Principal Investigator. Jul 2014-Jun 2016. 1R21NS084885-01A1.
Disordered Wnt/b-catenin signaling in MPNST Development and Maintenance. Co-Principal Investigator. Oct 2014-Sep 2019. 1R01NS086219-01A1.
Can targeted therapy prevent neurofibroma growth in mice? Principal Investigator. Neurofibromatosis Therapeutic Acceleration Program (NTAP). Sep 2014-Aug 2016.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center